Literature DB >> 15151139

[A 32-year old male patient with pathological humeral fracture, splenomegaly and thrombocytopenia].

E M Dürr1, H C Geiss, B F Pontz, K G Parhofer.   

Abstract

We describe the case of a 32-year old male patient who presented with a pathological fracture of his right humerus, splenomegaly and thrombocytopenia, the typical symptoms of Gaucher's disease, a lysosomal storage disease. Diagnosis was confirmed by bone marrow biopsy (detection of lipid engorged macrophages - Gaucher cells), by a markedly diminished activity of acid, beta-Glucosidase and by showing two different mutations (764T/A, 1187G/A) in the gene encoding acid beta-Glucosidase. The first mutation causes an amino-acid substitution (phenylalanine to tyrosine). The second mutation causes a premature termination at amino-acid position 396. Enzyme replacement therapy was started with 60 Units/kg body weight, because of severe bone symptoms. Following the decrease in spleen size and increase in platelet count the dose was gradually tapered to 20 U/kg. After two years of enzyme replacement therapy platelet count and spleen volume have normalized and the bone lesions have almost disappeared.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15151139     DOI: 10.1007/s00108-003-1121-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  6 in total

Review 1.  Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses.

Authors:  T M Cox
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

Review 2.  [Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000].

Authors:  C Niederau; A Rolfs; S vom Dahl; D Häussinger; L W Poll; E Mengel; M Beck
Journal:  Med Klin (Munich)       Date:  2001-01-15

3.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

4.  Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.

Authors:  Neal J Weinreb; Joel Charrow; Hans C Andersson; Paige Kaplan; Edwin H Kolodny; Pramod Mistry; Gregory Pastores; Barry E Rosenbloom; C Ronald Scott; Rebecca S Wappner; Ari Zimran
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965

5.  Enzyme replacement therapy for Gaucher disease.

Authors:  E Beutler; A Kay; A Saven; P Garver; D Thurston; A Dawson; B Rosenbloom
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113

6.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

  6 in total
  1 in total

1.  [A 56-year-old patient with Gaucher's disease sustaining a pathologic subcapital fracture of the humerus].

Authors:  M Janke; M Börner; E Mueller-Garamvölgyi; R Hess
Journal:  Orthopade       Date:  2008-03       Impact factor: 1.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.